TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight ≥ 40 kg;~* Recurrent abdominal pain or discomfort for three or more days per month for the last three months which meets Rome III criteria for non-constipating IBS;~* Patients on a stable diet for at least eight weeks;~* Patients ≥ 50 years of age with a negative screening colonoscopy in the last five years;~* Able and willing to comply with all protocol procedures for the planned duration of the study;~* Able and willing to understand, sign and date an informed consent document, and authorize access to protected health information,~* Females must be postmenopausal, surgically incapable of bearing children, or practicing a reliable method of birth control (intrauterine devices, spermicide and barrier) (Hormonal contraceptives are NOT regarded as adequate for the purpose of this trial.) Partner/spouse sterility may also qualify at the Investigator's discretion. Females of child-bearing potential must have a negative urine pregnancy test at baseline.~Exclusion Criteria:~* Constipating IBS;~* History of untreated lactose intolerance;~* History of colonic or major abdominal surgery (colectomy, for example);~* Active (untreated) Thyroid disease;~* Current diagnosis of major depression or psychosis;~* Known positive stool cultures for Clostridium difficile or other pathogens;~* Any condition necessitating the administration of analgesics (except paracetamol), probiotics, neuroleptics, antidepressants for IBS symptoms, daytime tranquilizers, prokinetics or spasmolytic medications;~* Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling;~* Other major physical or major psychiatric illness within the last six months that in the opinion of the investigator would affect the patient's ability to complete the trial;~* Uncontrolled systemic disease such as diabetes;~* Patients undergoing chemotherapy for the treatment of cancer;~* Known hypersensitivity or contraindication to any component of the test product (study drugs) or diagnostics used;~* Participation in another study within eight (8) weeks prior to the study;~* Unable to attend all visits required by the protocol;~* Female patients must be excluded if they are pregnant, breast feeding, or planning to become pregnant during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AST-120, 2 gram sachets
- 2 (Type: PLACEBO_COMPARATOR): Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tramadol Hydrochloride and Dexketoprofen Trometamol for the Oral Treatment of Moderate to Severe Acute Pain Following Removal of Impacted Lower Third Molar

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients aged more than 18 years. Females participating in the study must be either non-childbearing potential or routinely using an effective method of birth control resulting in a low failure rate.~* Scheduled for outpatient surgical extraction -under local anaesthesia of lower third molar teeth, with at least one partially impacted in the mandible requiring bone manipulation.~* Pain of at least moderate intensity in the first 4 hours after the end of surgery (NRS score ≥ 4).~Exclusion Criteria:~* History of allergy or hypersensitivity to the study treatments, RM or to any other NSAIDs, opioids and acetyl salicylic acid.~* History of peptic ulcer, gastrointestinal disorders by NSAIDs or gastrointestinal bleeding or other active bleedings.~* History of any illness or condition that, in the opinion of the Investigator might pose a risk to the patient or confound the efficacy and safety results of the study.~* Patients using and not suitable for withdrawing the prohibited medications specified in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tramadol/Dexketoprofen (Type: EXPERIMENTAL): Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose;~Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x \[37.5mg/325mg\] film-coated tablets, oral single dose.
- Tramadol/Paracetamol (Type: ACTIVE_COMPARATOR): Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x \[37.5mg/325mg\] film-coated tablets, oral single dose;~Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.~.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;~Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Regional Analgesia After Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* obtained consent~* singleton pregnancy~* subarachnoid anaesthesia~Exclusion Criteria:~* coagulopathy~* allergy to morphine and local anesthetics~* depression, antidepressant drugs treatment~* epilepsy~* usage of painkiller before surgery~* addiction to alcohol or recreational drugs

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PCA (Type: EXPERIMENTAL): Subarchnoid anesthesia with bupivacaine PCA with morphine in the PACU
- TAP (Type: EXPERIMENTAL): Subarchnoid anesthesia with bupivacaine TAP (transversus abdominis plane block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.~PCA with morphine in the PACU
- QLB (Type: EXPERIMENTAL): Subarchnoid anesthesia with bupivacaine QLB (quadratus lumborum block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.~PCA with morphine in the PACU

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has a documented clinical diagnosis of asthma defined by the ATS for at least 6 months prior to Visit 2~* Have a morning pre-bronchodilator clinic FEV1 measured at least 6 hours after the last dose of inhaled SABA and at least 48 hours after last dose of inhaled LABA of 60% to 100% of predicted normal~* Demonstrated reversibility of clinic FEV1 of ≥12% from pre -albuterol/salbutamol level within 15 to 30 minutes after administration of a standard dose of albuterol/salbutamol.~Exclusion Criteria:~* Have been hospitalized at least once or required emergency treatment more than once for an asthma-related condition during the 6 months prior to Visit 1~* Have required treatment with systemic corticosteroids (eg, oral, parenteral, or rectal) for any reason within the 6 weeks prior to Visit 1

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Symbicort pMDI 80/2.25 µg (Type: ACTIVE_COMPARATOR): Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
- Symbicort pMDI 80/4.5µg (Type: ACTIVE_COMPARATOR): Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
- Budesonide pMDI (Type: ACTIVE_COMPARATOR): Budesonide pMDI 80µg, 2 acuations twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes treated with insulin for at least 12 months~* Planning to become pregnant and have a screening HbA1c (glycosylated haemoglobin) lesser than or equal to 9.0%, or~* Pregnant with an intrauterine singleton living foetus, 8-12 weeks pregnant when joining the trial and a HbA1c lesser than or equal to 8.0% when pregnancy is confirmed~Exclusion Criteria:~* Known or suspected hypersensitivity to the trial product(s) or related products~* Untreated hyperthyroidism or hypothyroidism~* Known or suspected abuse of alcohol or narcotics~* Cardiac problems~* Impaired kidney function~* History of severe hyperemesis gravidarum~* Treatment with in-vitro fertilisation or other medical infertility treatment~* Impaired liver function~* Uncontrolled hypertension~* Proliferative retinopathy or maculopathy requiring acute treatment~* Known to be HIV (human immunodeficiency virus) positive, Hepatitis B or Hepatitis C positive~* Any concomitant medication contraindicated in pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin detemir (Type: EXPERIMENTAL): Individually adjusted insulin detemir injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
- Neutral Protamine Hagedorn (NPH) insulin (Type: ACTIVE_COMPARATOR): Individually adjusted NPH insulin injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Pathologically confirmed non-small cell lung cancer~  * Stage IIIB or IV or recurrent disease~* Measurable or evaluable indicator lesions~* Must have smoked ≥ 100 cigarettes in his/her lifetime~PATIENT CHARACTERISTICS:~* Karnofsky performance status 70-100%~* WBC ≥ 4,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min~* Bilirubin ≤ 1.0 mg/dL~* AST ≤ 2.5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for ≥ 1 week after completion of study treatment~* No gastrointestinal tract disease or inability to take oral medication~* No prior malignancy within the past 2 years except nonmelanoma skin cancer or carcinoma in situ of the cervix~* No other active medical problems, including severe infection, unstable angina, or myocardial infarction within the past 6 months~* No poorly controlled hypertension or severe malnutrition~* No New York Heart Association class III or IV congestive heart failure or serious cardiac arrhythmia requiring medication except chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia)~PRIOR CONCURRENT THERAPY:~* At least 3 weeks since prior radiotherapy to major bone marrow-containing sites~* No prior chemotherapy for advanced non-small cell lung cancer~* No prior agents directed at the epidermal growth factor receptor (EGFR)/HER axis (e.g., gefitinib, cetuximab, or trastuzumab \[Herceptin®\])~* No prior surgical procedure resulting in abnormal absorption of oral medications~* No concurrent surgical resection, palliative radiotherapy, or hormonal therapy~* No other concurrent anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- 150 PRE (Type: EXPERIMENTAL): Erlotinib 150mg on days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200 mg/m2
- 1,500 PRE (Type: EXPERIMENTAL): Erlotinib 1500mg on Days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200mg/m2
- 1,500 POST (Type: EXPERIMENTAL): Carboplatin AUC6, Paclitaxel 200 mg/m2 followed by Erlotinib 1500mg days 2 and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Healthy male and female subjects~* age of 18 to 55 years~* body mass index (BMI) of 18.5 to 29.9 kg/m2~* additional inclusion criteria may apply~Exclusion criteria:~* Any finding in the medical examination (including BP, PR or ECG) deviating from normal and judged as clinically relevant by the investigator~* Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg or diastolic blood pressure outside the range of 50 to 90 mmHg or pulse rate outside the range of 45 to 90 bpm~* Any laboratory value outside the reference range that the investigator considers to be of clinical relevance~* Any evidence of a concomitant disease judged as clinically relevant by the investigator~* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders~* Surgery of the gastrointestinal tract that could interfere with kinetics of the trial medication~* Diseases of the central nervous system (including but not limited to any kind of seizures and stroke), and other relevant neurological disorders or psychiatric disorders~* additional exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Fixed dose combination (Type: EXPERIMENTAL): Single dose empagliflozin/metformin
- Single tablets combination (Type: ACTIVE_COMPARATOR): single doses empagliflozin and metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed early adenocarcinoma of the breast~  * Completely excised by surgery with curative intent (R0)~    * Any N OR~   * Any primary tumor greater than 3 cm OR~   * Any primary tumor grade III and greater than 1 cm~ * M0~* No positive supraclavicular nodes~* Hormone receptor status:~  * Estrogen and/or progesterone receptor positive~PATIENT CHARACTERISTICS:~Age:~* Any age~* See Menopausal status~Sex:~* Female~Menopausal status:~* Postmenopausal~  * Any age with bilateral oophorectomy or amenorrhea for at least 5 years OR~ * Age 50 or over:~    * Natural amenorrhea for at least 1 year OR~   * Chemotherapy-induced amenorrhea for at least 2 years OR~   * Radiation-induced amenorrhea (at least 3 months since prior radiotherapy) OR~ * Under age 50:~    * If amenorrheic for less than 5 years (any cause) or prior hysterectomy without bilateral surgical oophorectomy, follicle-stimulating hormone must be assayed to confirm postmenopausal status~Performance status:~* ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Platelet count greater than 100,000/mm3~* WBC greater than 3,000/mm3~Hepatic:~* SGOT or SGPT less than 2.5 times upper limit of normal (ULN)~Renal:~* Creatinine less than 1.5 times ULN~Cardiovascular:~* No uncontrolled cardiac disease~* No unstable angina~* No congestive heart failure or arrhythmia requiring medical therapy~* No myocardial infarction within the past 3 months~Other:~* No severe osteoporosis~* No other malignancies within the past 5 years except adequately treated carcinoma in situ of the cervix or basal cell skin cancer~* No other serious concurrent disease that would preclude study~* No psychiatric disorders that would preclude study~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior neoadjuvant chemotherapy~* No more than 10 weeks since completion of prior adjuvant chemotherapy~Endocrine therapy:~* No prior adjuvant hormonal therapy for breast cancer~* No prior neoadjuvant hormonal therapy (prior to surgery) for duration of more than 4 weeks~* At least 4 weeks since prior hormone replacement therapy~Radiotherapy:~* Not specified~Surgery:~* See Disease Characteristics~* No more than 10 weeks since completion of curative surgery~Other:~* No other concurrent investigational agents or participation in another clinical study (except adjuvant cytotoxic chemotherapy studies)~* Concurrent bisphosphonates allowed

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Hyperuricemia (serum uric acid ≥8.0 mg/dL).~* Must meet American College of Rheumatology criteria for gout.~* Must have adequate renal function (serum creatinine \<1.5 mg/dL).~* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.~Exclusion Criteria:~* History of xanthinuria~* Alcohol consumption \>14/week~* Has a history of significant concomitant illness.~* Has active liver disease.~* Has a body mass index greater than 50 kilogram per meter² (kg/m²)~* Any other significant medical condition that would interfere with the treatment, safety or compliance with the protocol, as defined by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo QD (Type: PLACEBO_COMPARATOR): None
- Febuxostat 40 mg QD (Type: EXPERIMENTAL): None
- Febuxostat 80 mg QD (Type: EXPERIMENTAL): None
- Febuxostat 120 mg QD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PNH~* Clinically Evident EVH defined by:~  * Anemia (Hgb ≤9.5 gram/deciliter) with absolute reticulocyte count ≥120 x 10\^9/liter~* Receiving an approved C5 inhibitor for at least 6 months prior to Day 1~* Platelet count ≥30,000/microliters (µL)~* Absolute neutrophil counts ≥500/μL~* Documentation of/or willingness to receive vaccinations for N. meningiditis and prophylactic antibiotics as required~Exclusion Criteria:~* History of a major organ transplant or hematopoietic stem cell transplantation (HSCT)~* Participants with known aplastic anemia or other bone marrow failure that requires HSCT or other therapies including anti-thymocyte globulin and/or immunosuppressants~* Known or suspected complement deficiency~* Laboratory abnormalities at screening, including:~  * Alanine aminotransferase \>2 x ULN (\>3 x ULN in case of patients with documented liver iron overload defined by serum ferratin values~    * 500 ng/ML)~ * Direct bilirubin \>2 x ULN (unless due to EVH or documented Gilbert's Syndrome)~* Current evidence of biliary cholestasis~* Estimated glomerular filtration rate of \<30 milliliters/minute/1.73 meter squared and/or are on dialysis~* Evidence of human immunodeficiency virus, hepatitis B, or active hepatitis C infection at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Danicopan + C5 Inhibitor (Type: EXPERIMENTAL): Participants will receive danicopan, in addition to their C5 inhibitor therapy, for 24 weeks (12 weeks in Treatment Period 1, followed by 12 weeks in Treatment Period 2).
- Placebo + C5 Inhibitor (Type: PLACEBO_COMPARATOR): Participants will receive placebo, in addition to their C5 inhibitor therapy, for 12 weeks during Treatment Period 1. At Week 12, participants randomized to receive placebo will be switched to danicopan for an additional 12 weeks (Treatment Period 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete